GlassScriptPhysician profile
Tabitha Flowers Arrington
NPI 1225646110
$6,705.22
in general payments reported to CMS, 2019-2025
27 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,060 · 2022: $1,325 · 2023: $1,158 · 2024: $1,601 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.69 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,535.54 | 2021-2025 | |
| Axsome Therapeutics, INC. | $658.32 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $638.78 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $638.20 | 2021-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $430.92 | 2022-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $418.11 | 2022-2024 | Spravato |
| Corium, LLC | $313.64 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $288.61 | 2021-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $257.25 | 2024-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $205.62 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $152.12 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $148.95 | 2023 | Quviviq |
| Tris Pharma INC | $147.87 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Novo Nordisk INC | $124.99 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $100.37 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $78.89 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.00 | 2023 | Lifevest |
| Biogen, INC. | $73.42 | 2024-2025 | Zurzuvae |
| Alkermes, INC. | $66.64 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.29 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.84 | 2024 | Relistor |
| Myriad Genetic Laboratories, INC. | $37.03 | 2024 | Genesight |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.48 | 2024 | |
| Eisai INC. | $20.15 | 2021 | |
| Neuronetics, INC. | $16.13 | 2024 | Neurostar Tms Therapy System |
| Tempus Ai, INC | $15.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Arrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.